The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Open accessAbstract
Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [32]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [32]
In the citing paper
“The study compared docetaxel with ramucirumab or placebo in patients who had progressed after platinum-based chemotherapy.Median OS was longer (10.5 versus 9.1 months, HR 0.86, 95% CI: 0.75-0.98,P = 0.023) in the ramucirumab arm compared with the placebo arm.Median PFS was also superior in the ramucirumab arm”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [94]
In the citing paper
“One trial tested a new vascular endothelial growth factor inhibitor for NSCLC, ramucirumab (plus docetaxel); the intervention arm experienced longer PFS (by 1.5 months) and OS (by 1.4 months), both statistically significant.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [57]
In the citing paper
“Hematologic adverse events were more frequent with ramucirumab plus docetaxel, as were other adverse events, such as diarrhea, dyspnea, and fatigue.57”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [57]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citationJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948
Research works printed but not linked: 1
- Wilke, 2014, J Clin Oncol, 32
Cited by
Sorted by citations
Items 301–400 of 1,001
Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Furukawa, K., Nagano, T., TACHIHARA, M. Y., Yamamoto, M., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173900 · Cited by 36
Modern therapies of nonsmall cell lung cancer
Jachowski, A., Marcinkowski, M., Szydłowski, J., Grabarczyk, O., Nogaj, Z., Marcin, L. P., Pławski, A., Jagodziński, P. P., & Słowikowski, B. K. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00786-4 · Cited by 36
Hussain, M., Rathkopf, D. E., Liu, G., Armstrong, A. J., Kelly, W. K., Ferrari, A. C., Hainsworth, J. D., Joshi, A., Hozak, R. R., Yang, L., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.019 · Cited by 34
Popat, S., Mellemgaard, A., Fahrbach, K. R., Martin, A. L., Rizzo, M., Kaiser, R., Griebsch, I., & Reck, M. (2014) · Future Oncology · doi:10.2217/fon.14.290 · Cited by 34
Self-citationNew developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Hirsh, V. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s104177 · Cited by 36
Perdrizet, K., & Leighl, N. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0617-6 · Cited by 36
Vickers, A. D., Winfree, K. B., Carter, G. C., Kiiskinen, U., Jen, M., Stull, D. E., Kaye, J. A., & Carbone, D. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5569-5 · Cited by 34
Lim, J. S. J., & Soo, R. A. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816661091 · Cited by 33
Overall survival in non-small cell lung cancer-what is clinically meaningful?
Fenchel, K., Sellmann, L., & Dempke, W. C. M. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.06 · Cited by 33
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 36
Brueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Stenzinger, A., Tufman, A., Hoffknecht, P., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-197 · Cited by 32
Self-citationFan, R., Lan, M., Gao, X., Wang, Y., Xiang, M., Zheng, Y., Tong, A., Zhang, X., Han, B. R., Zhou, L., et al. (2017) · Advanced Science · doi:10.1002/advs.201600285 · Cited by 33
Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Melosky, B. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00256 · Cited by 33
Nintedanib in non-small cell lung cancer: from preclinical to approval
Caglevic, C., Grassi, M., Raez, L. E., Listì, A., Giallombardo, M., Bustamante, E. I., Bazo, I. G., & Rolfo, C. D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815579608 · Cited by 32
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives
Minguet, J., Smith, K. H., Bramlage, C. P., & Bramlage, P. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2770-3 · Cited by 32
Brueckl, W. M., Reck, M., Rittmeyer, A., Kollmeier, J., Wesseler, C., Wiest, G. H., Christopoulos, P., Tufman, A., Hoffknecht, P., Ulm, B., et al. (2020) · Clinical Medicine Insights Oncology · doi:10.1177/1179554920951358 · Cited by 33
Self-citationAzar, I. H., Alkassis, S., Fukui, J. A., Alsawah, F., Fedak, K., Hallak, M. N. A., Sukari, A. W., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s307324 · Cited by 37
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
Anderson, T. S., McCormick, A. L., Piersall, S. L., Okpalanwaka, I. F., & Lowe, D. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.009 · Cited by 32
Tuning core hydrophobicity of spherical polymeric nanoconstructs for docetaxel delivery
Mascolo, D. D., Basnett, P., Palange, A. L., Francardi, M., Roy, I., & Decuzzi, P. (2016) · Polymer International · doi:10.1002/pi.5072 · Cited by 32
Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)
Tanaka, F., & Yoneda, K. (2015) · Surgery Today · doi:10.1007/s00595-015-1174-7 · Cited by 31
Sands, J. M., Li, Q., & Hornberger, J. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.014 · Cited by 31
Xiong, Q., Qin, B., Xin, L., Yang, B. Y., Song, Q., Wang, Y., Zhang, S., & Hu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659380 · Cited by 33
Reck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 32
Self-citationGoldstein, D. A., & El‐Rayes, B. F. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0028 · Cited by 30
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
Felip, E., Hirsh, V., Popat, S., Cobo, M., Fülöp, A., Dayen, C., Trigo, J. M., Gregg, R. W., Waller, C. F., Soria, J., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.002 · Cited by 30
Chen, H., Shien, K., Suzawa, K., Tsukuda, K., Tomida, S., Sato, H., Torigoe, H., Watanabe, M., Namba, K., Yamamoto, H., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6678 · Cited by 30
Rihawi, K., Gelsomino, F., Sperandi, F., Melotti, B., Fiorentino, M., Casolari, L., & Ardizzoni, A. (2017) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817725486 · Cited by 30
Yoshimura, A., Yamada, T., Okuma, Y., Kitadai, R., Takeda, T., Kanematsu, T., Goto, H., Yoneda, H., Harada, T., Kubota, Y., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.07 · Cited by 30
Nasir, A., Holzer, T. R., Chen, M., Man, M. Z., & Schade, A. E. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0427-5 · Cited by 30
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29
Tabchi, S., & Blais, N. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00052 · Cited by 29
Recent advances in the management of non-small cell lung cancer
Shojaee, S., & Nana-Sinkam, P. S. (2017) · F1000Research · doi:10.12688/f1000research.11471.1 · Cited by 29
Fernández‐Ruiz, M., García‐Campelo, R., Garrido-Castro, A. C., & Ruíz-Camps, I. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.027 · Cited by 29
Reck, M., Garassino, M. C., Imbimbo, M., Shepherd, F. A., Socinski, M. A., Shih, J., Tsao, A. S., Lee, P., Winfree, K. B., Sashegyi, A. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.03.025 · Cited by 29
Self-citationKatiyar, V., Chesney, J. A., & Kloecker, G. H. (2023) · Cancers · doi:10.3390/cancers15143733 · Cited by 32
Kotsakis, A. P., Matikas, A., Koinis, F., Kentepozidis, N. K., Varthalitis, I. I., Karavassilis, V., Samantas, E., Katsaounis, P., Dermitzaki, E. K., Hatzidaki, D., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.281 · Cited by 28
Bazzazi, H., & Popel, A. S. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005332 · Cited by 30
Lü, S., Chang, J., Liu, X., Shi, J., Lü, Y., Li, W., Yang, J., Zhou, J., Wang, J., An, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7145 · Cited by 29
Tagliamento, M., Genova, C., Rossi, G., Coco, S., Rijavec, E., Bello, M. G. D., Boccardo, S., Grossi, F., & Alama, A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1627326 · Cited by 29
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28
Song, D. H., Ko, G. H., LEE, J. H., Lee, J. S., LEE, G.-W., Kim, H. C., Yang, J. W., Heo, R. W., Roh, G. S., Han, S., et al. (2015) · Oncology Letters · doi:10.3892/ol.2015.3988 · Cited by 28
Semrad, T. J., Kim, E. J.-H., Tanaka, M. S., Sands, J. M., Roberts, C., Burich, R. A., Li, Y., Gandara, D. R., Lara, P. N., & Mack, P. C. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.12.002 · Cited by 28
Different treatment efficacies and side effects of cytotoxic chemotherapy
Li, L.-J., Chong, Q.-Y., Wang, L., Cher, G. B., & Soo, R. A. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.63 · Cited by 27
Shaikh, S. B., & Bhandary, Y. P. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13684 · Cited by 28
Salous, T., Shukla, N. A., Althouse, S. K., Perkins, S. M., Furqan, M., Leal, T. A. B., Traynor, A. M., Feldman, L. E., Hanna, N. H., & Durm, G. A. (2022) · Cancer · doi:10.1002/cncr.34565 · Cited by 29
Reck, M., Mellemgaard, A., von Pawel, J., Gottfried, M., Bondarenko, I., Cheng, Y., Zarogoulidis, K., Luft, A. V., Bennouna, J., Barrueco, J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.003 · Cited by 28
Self-citationLei, X., Li, Z., Huang, M., Huang, L., Huang, Y., Lv, S., Zhang, W., Chen, Z., Ke, Y., Li, S., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03003-0 · Cited by 27
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Goss, G. D., & Spaans, J. N. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0209 · Cited by 28
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
Fang, S., Zhang, H., Zhang, Y., & Xie, W. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s126613 · Cited by 27
Pujol, J.-L., Vansteenkiste, J., Rodríguez, L. P.-A., Gregorc, V., Mazières, J., Awad, M. M., Janne, P. A., Chisamore, M. J., Hossain, A. M., Chen, Y., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100234 · Cited by 27
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer
Suzuki, J., Tsuboi, M., & Ishii, G. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2019018 · Cited by 22
Feng, S., Wang, G., Zhang, J., Xie, Y., Sun, R., Fei, F., Huang, J., Wang, Y., Aa, J., & Zhou, F. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.16 · Cited by 27
Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
Tang, J. P., Li, X. Y., Liang, J., Wu, D. P., Peng, L. H., & Li, X. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15288447760357 · Cited by 27
Sone, K., Oguri, T., Uemura, T., Takeuchi, A., Fukuda, S., Takakuwa, O., Maeno, K., Fukumitsu, K., Kanemitsu, Y., Ohkubo, H., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5438-2 · Cited by 27
Tanaka, H., Taima, K., Itoga, M., Ishioka, Y., Baba, K., Shiratori, T., Sakamoto, H., Tsuchiya, J., Nakagawa, H., Hasegawa, Y., et al. (2019) · Medical Oncology · doi:10.1007/s12032-019-1278-9 · Cited by 27
Phage therapy as a revitalized weapon for treating clinical diseases
Wang, Y., & Yu, Y. (2025) · Microbiome Research Reports · doi:10.20517/mrr.2025.31 · Cited by 28
Gadgeel, S. M., Goss, G. D., Soria, J., Felip, E., Georgoulias, V., Lü, S., Cobo, M., Syrigos, K., Lee, K. H., Göker, E., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.010 · Cited by 27
Self-citationGuirgis, H. M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0320-3 · Cited by 26
Abdel-Maged, A. E.-S., Gad, A. M., Wahdan, S. A., & Azab, S. S. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114702 · Cited by 27
Management of Lung Cancer in the Elderly
Gajra, A., Akbar, S., & Din, N. U. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.008 · Cited by 28
Raphael, J., Chan, K., Karim, S., Kerbel, R. S., Lam, H., Santos, K. D., Saluja, R., & Verma, S. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.004 · Cited by 26
Yoshino, T., Yamazaki, K., Gotoh, M., Nasroulah, F., Gao, L., Yoshizuka, N., & Ohtsu, A. (2015) · PubMed · Cited by 26
Genetic alteration profiling of patients with resected squamous cell lung carcinomas
Tao, D., Han, X., Zhang, N., Lin, D., Wu, D., Zhu, X., Song, W., & Shi, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9096 · Cited by 25
Tomasini, P., Brosseau, S., Mazières, J., Merlio, J., Beau‐Faller, M., Mosser, J., Wislez, M., Ouafik, L., Besse, B., Rouquette, I., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00514-2017 · Cited by 27
van der Weijst, L., Lievens, Y. N., Schrauwen, W., & Surmont, V. F. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00715 · Cited by 25
New Immuno-oncology Targets and Resistance Mechanisms
Tokaz, M. C., Baik, C. S., Houghton, A. M., & Tseng, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01005-8 · Cited by 25
Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
Moliner, L., Spurgeon, L. C., & Califano, R. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100879 · Cited by 26
A review of 2014 cancer drug approvals, with a look at 2015 and beyond.
Butler, T. W., Maravent, S., Boisselle, J., Valdés, J. A. M., & Fellner, C. (2015) · Europe PMC (PubMed Central) · Cited by 25
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Bluthgen, M. V., & Besse, B. (2015) · European Respiratory Review · doi:10.1183/16000617.00002115 · Cited by 25
Tubulin inhibitors in non-small cell lung cancer: looking back and forward
Ferrara, R., Pilotto, S., Peretti, U., Caccese, M., Kinspergher, S., Carbognin, L., Karachaliou, N., Rosell, R., Tortora, G., & Bria, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1157581 · Cited by 25
Morgensztern, D., Karaseva, N. A., Felip, E., Delgado, I., Burdaeva, O. N., Dómine, M., Lara, P. N., Paik, P. K., Lassen, U., Орлов, С. В., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.011 · Cited by 25
Self-citationXu, J., Tian, L., Qi, W., Lv, Q., & Wang, T. (2024) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001088 · Cited by 29
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 25
Self-citationBeyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges
Mountzios, G., Naidoo, J., Wang, C., Creelan, B., Trotier, D., Campbell, T. C., & Peters, S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432526 · Cited by 24
Han, B., Feinstein, T. M., Shi, Y., Chen, G., Yu, Y., Hu, C., Shi, J., Feng, J., Wu, H., Cheng, Y., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00178-4 · Cited by 24
Patel, N., Patel, M., Patel, A., Patel, S., Sakariya, D., Parmar, A., Sarkar, R., Patel, M., Rohit, S., Patel, S., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140392 · Cited by 24
Leighl, N. B., Paz-Ares, L. G., Rodríguez‐Abreu, D., Hui, R., Baka, S., Bigot, F., Nishio, M., Smolin, A., Ahmed, S. I., Schoenfeld, A. J., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.020 · Cited by 24
Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma
Zeng, D., Wang, C., Lei, W., Huang, J., & Jiang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19908 · Cited by 24
Frega, S., Maso, A. D., Ferro, A., Bonanno, L., Conte, P., & Pasello, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.012 · Cited by 25
Targeting un-MET needs in advanced non-small cell lung cancer
Coleman, N., Harbery, A., Heuss, S. F., Vivanco, I., & Popat, S. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.016 · Cited by 25
Nintedanib in NSCLC: evidence to date and place in therapy
Bronte, G., Passiglia, F., Galvano, A., Barraco, N., Listì, A., Castiglia, M., Rizzo, S., Fiorentino, E., Bazan, V., & Russo, A. D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016630976 · Cited by 24
Albaba, H., Lim, C. H., & Leighl, N. B. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0563-8 · Cited by 24
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
Pàez‐Ribes, M., Man, S., Xu, P., & Kerbel, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0915 · Cited by 23
Cheng, J.-D., Chai, L., Zhao, Z., Hao, Y., & Li, S. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253366 · Cited by 23
Fala, L. (2015) · PubMed · Cited by 23
Gerber, D. E., Spigel, D. R., Giorgadze, D., Shtivelband, M. I., Ponomarova, O. V., Shan, J. S., Menander, K. B., & Belani, C. P. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.02.003 · Cited by 23
Wu, D., Liang, L., Nie, L., Nie, J., Dai, L., Hu, W., Zhang, J., Chen, X., Han, J., Ma, X., et al. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12870 · Cited by 23
Smit, E. F., Garon, E. B., Reck, M., Cappuzzo, F., Bidoli, P., Cohen, R. B., Gao, L., O’Brien, L. M., Lee, P., Zimmermann, A. H., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3560-5 · Cited by 23
Self-citationKim, E. S., Kelly, K. L., Paz-Ares, L. G., Garrido, P., Jalal, S. I., Mahadevan, D., Gutierrez, M. E., Provencio, M., Schaefer, E. S., Shaheen, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0651 · Cited by 23
Cantelmo, A. R., Dejos, C., Kocher, F., Hilbe, W., Wolf, D. G. F., & Pircher, A. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000591 · Cited by 23
Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22
Yao, J., Wang, Z., Sheng, J., Wang, H., You, L., Zhu, X., Pan, H., & Han, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107033 · Cited by 22
Kobayashi, T., Iwama, S., Yamagami, A., Yasuda, Y., Okuji, T., Ito, M., Zhou, X., Ando, M., Onoue, T., Miyata, T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac467 · Cited by 22
Current Trends in Cancer Therapy
Sekhon, N., Kumbla, R. A., & Mita, M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803547-4.00001-x · Cited by 23
Fayçal, C. A., Brambilla, E. M., Agorreta, J., Lepeltier, N., Jacquet, T., Lemaître, N., Emadali, A., Lucas, A., Lacal, P. M., Montuenga, L. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0128-4 · Cited by 22
Qin, A., Wells, L., Malhotra, B., Gadgeel, S. M., Schneider, B. J., Ramnath, N., Rice, J. D., & Kalemkerian, G. P. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.10.011 · Cited by 22
Lung cancer as a cardiotoxic state: a review
Pérez-Callejo, D., Torrente, M., Brenes, M. A., Núñez, B., & Provencio, M. (2017) · Medical Oncology · doi:10.1007/s12032-017-1012-4 · Cited by 23
Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Nosaki, K., Kohno, T., Tsuta, K., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.03.002 · Cited by 21
Metadata
- Authors
- Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
- Affiliations
- University of California, Los Angeles (US)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Instituto Nacional de Cancerología (MX)
- Tata Memorial Hospital (IN)
- Sotiria General Hospital (GR)
- Samsung Medical Center (KR)
- Russian Cancer Research Center NN Blokhin (RU)
- Charing Cross Hospital (GB)
- University Hospital Heidelberg (DE)
- Azienda Ospedaliera San Gerardo (IT)
- Cancer Center of Kansas (US)
- Gemeinschaftskrankenhaus Herdecke (DE)
- Yonsei University Health System (KR)
- Institutul Oncologic Bucuresti (RO)
- City Clinical Oncology Center (RU)
- German Center for Lung Research (DE)
- Ospedale di Livorno (IT)
- Eli Lilly (United States) (US)
- Corresponding author
- Garon, Edward B
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 384
- Issue
- 9944
- Pages
- 665-673
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2140980839
- Cited by
- 1,309
- References
- 35
- Citations by year
- 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
- FWCI
- 116.89
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
- MeSH terms
- Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
